Trials / Completed
CompletedNCT01223014
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers
An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 50 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of \[14C\]AZD2423 in healthy male volunteers aged 50 to 65 years (inclusive).The purpose of this study is to investigate how and how quickly AZD 2423 or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2423 | AZD2423 |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2010-10-18
- Last updated
- 2011-02-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01223014. Inclusion in this directory is not an endorsement.